Literature DB >> 22394260

Short communication: adhesion pathways utilized by HIV-infected lymphocytes.

Yu-hua Chow1, Li Liu, Barbara Schwartz, John M Harlan, Lynn M Schnapp.   

Abstract

We recently reported a novel adhesion pathway in lymphocytes that is mediated by cyclin-dependent kinase (Cdk) 4 activity and mediates lymphocyte interactions with endothelial matrix. We now demonstrate that HIV-infected lymphocytes also use Cdk4 to mediate spontaneous adhesion to fibronectin and endothelial matrix. We further demonstrate that HIV-infected lymphocytes require Rap-1 activity for phorbol-stimulated adhesion. Understanding adhesion pathways used by HIV-infected lymphocytes may lead to interventions to regulate aberrant adhesion and migration.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22394260      PMCID： PMC3505057          DOI： 10.1089/AID.2011.0262

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


  24 in total

1.  Superfibronectin, a multimeric form of fibronectin, increases HIV infection of primary CD4+ T lymphocytes.

Authors:  M C Tellier; G Greco; M Klotman; A Mosoian; A Cara; W Arap; E Ruoslahti; R Pasqualini; L M Schnapp
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

2.  In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).

Authors:  Steven J McClue; David Blake; Rosemary Clarke; Angela Cowan; Lorna Cummings; Peter M Fischer; Mairi MacKenzie; Jean Melville; Kevin Stewart; Shudong Wang; Nikolai Zhelev; Daniella Zheleva; David P Lane
Journal:  Int J Cancer       Date:  2002-12-10       Impact factor: 7.396

3.  Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1.

Authors:  I Matushansky; F Radparvar; A I Skoultchi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

4.  Matrix fibronectin increases HIV stability and infectivity.

Authors:  Giampaolo Greco; Sampa Pal; Renata Pasqualini; Lynn M Schnapp
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

5.  p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.

Authors:  Marie Knockaert; Philippe Lenormand; Nathanael Gray; Peter Schultz; Jacques Pouysségur; Laurent Meijer
Journal:  Oncogene       Date:  2002-09-19       Impact factor: 9.867

6.  HIV-infected lymphocytes regulate fibronectin synthesis by TGF beta 1 secretion.

Authors:  Sampa Pal; Lynn M Schnapp
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

7.  The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.

Authors:  Steven R Whittaker; Mike I Walton; Michelle D Garrett; Paul Workman
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

8.  The GTPase Rap1 regulates phorbol 12-myristate 13-acetate-stimulated but not ligand-induced beta 1 integrin-dependent leukocyte adhesion.

Authors:  Li Liu; Barbara R Schwartz; Joan Tupper; Nancy Lin; Robert K Winn; John M Harlan
Journal:  J Biol Chem       Date:  2002-06-28       Impact factor: 5.157

9.  Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins.

Authors:  Luis M Schang; Andrew Bantly; Marie Knockaert; Farida Shaheen; Laurent Meijer; Michael H Malim; Nathanael S Gray; Priscilla A Schaffer
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 10.  Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics.

Authors:  Cynthia de la Fuente; Anil Maddukuri; Kylene Kehn; Shanese Y Baylor; Longwen Deng; Anne Pumfery; Fatah Kashanchi
Journal:  Curr HIV Res       Date:  2003-04       Impact factor: 1.581
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.